Tokyo, Japan

Nobelpharma Co., Ltd.


USPTO Granted Patents = 9


Trademarks = 9

Forward Citations = 2

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Takako Aburada (4 out of 4 patents)

silverMedal Shin-ichi Kanemaru (3 out of 3 patents)

bronzeMedal Shinobu Yamada (1 out of 3 patents)

4.  Masanori Baba (1 out of 37 patents)

5.  Masaaki Toyama (1 out of 1 patent)

6.  Norikazu Sakakibara (1 out of 2 patents)

7.  Tetsuji Sanuki (1 out of 1 patent)

8.  Shuji Wakayoshi (1 out of 1 patent)

9.  Tsukasa Harada (1 out of 1 patent)

10.  Seiichi Masuda (1 out of 1 patent)

11.  Hiroyuki Nishihata (1 out of 1 patent)

12.  Kazuhiro Kinoshita (1 out of 2 patents)

13.  Kenichiro Nakao (1 out of 9 patents)

14.  Tasuku Harada (1 out of 1 patent)

15.  Fuminori Taniguchi (1 out of 1 patent)


9 patents:

Company Overview
Nobelpharma Co., Ltd. is a leading pharmaceutical company focused on developing innovative healthcare solutions. With a strong commitment to R&D, we strive to improve the quality of life for patients around the world. Our diverse product portfolio includes drugs for various therapeutic areas such as oncology, neurology, and cardiovascular health. Nobelpharma Co., Ltd. is dedicated to enhancing global healthcare through cutting-edge research and development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#2,020 in Tokyo

#4,699 in Japan

Tokyo, JP
Tokyo, Japan
Forward Citations = 2

16 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nobelpharma Co., Ltd.. Retrieved from https://idiyas.com/company/nobelpharma-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…